

**SYNTROPHARMA LIMITED**

**DIRECTORS' REPORT AND FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED 28 FEBRUARY 2014**

WEDNESDAY



SCT \*S3H2HVO1\*  
24/09/2014 #347  
COMPANIES HOUSE

# **SYNTROPHARMA LIMITED**

## **COMPANY INFORMATION**

<b>Directors</b>	A Gardiner P K Moore I J G Scott G McGettigan
<b>Registered number</b>	SC279236
<b>Registered office</b>	Excel House 30 Semple Street Edinburgh EH3 8BL
<b>Independent auditor</b>	BDO LLP Citypoint 65 Haymarket Terrace Edinburgh EH12 5HD
<b>Bankers</b>	Bank of Scotland 33 Channel Street Glasgow G2 1BE
<b>Solicitors</b>	MacRoberts LLP Excel House 30 Semple Street Edinburgh EH3 8BL

# **SYNTROPHARMA LIMITED**

## **CONTENTS**

	<b>Page</b>
<b>Directors' report</b>	<b>1</b>
<b>Directors' responsibilities statement</b>	<b>2</b>
<b>Independent auditor's report</b>	<b>3 - 4</b>
<b>Profit and loss account</b>	<b>5</b>
<b>Balance sheet</b>	<b>6</b>
<b>Notes to the financial statements</b>	<b>7 - 12</b>
<b>The following pages do not form part of the statutory financial statements:</b>	
<b>Detailed profit and loss account and summaries</b>	<b>13 - 15</b>

**SYNTROPHARMA LIMITED**

**DIRECTORS' REPORT  
FOR THE YEAR ENDED 28 FEBRUARY 2014**

The directors present their report and the financial statements for the year ended 28 February 2014.

**Principal activities**

The company's principal activity is that of drug development, in particular, the development and commercialisation of transdermal patch applications of drugs used to treat Central Nervous System disorders.

**Directors**

The directors who served during the year were:

A Gardiner  
P K Moore  
I J G Scott  
G McGettigan

**Provision of information to auditor**

Each of the persons who are directors at the time when this directors' report is approved has confirmed that:

- so far as that director is aware, there is no relevant audit information of which the company's auditor is unaware, and
- that director has taken all the steps that ought to have been taken as a director in order to be aware of any information needed by the company's auditor in connection with preparing its report and to establish that the company's auditor is aware of that information.

In preparing this report, the directors have taken advantage of the small companies exemptions provided by section 415A of the Companies Act 2006.

This report was approved by the board on

and signed on its behalf.



Director P K Moore

## **SYNTROPHARMA LIMITED**

### **DIRECTORS' RESPONSIBILITIES STATEMENT**

The directors are responsible for preparing the directors' report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom accounting standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period.

In preparing these financial statements the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgments and accounting estimates that are reasonable and prudent; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions, to disclose with reasonable accuracy at any time the financial position of the company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

## **SYNTROPHARMA LIMITED**

### **INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF SYNTROPHARMA LIMITED**

We have audited the financial statements of Syntropharma Limited for the year ended 28 February 2014 which comprise the profit and loss account, the balance sheet and the related notes. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

#### **Respective responsibilities of directors and auditor**

As explained more fully in the statement of directors' responsibilities, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view. Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Financial Reporting Council's (FRC's) Ethical Standards for Auditors.

#### **Scope of the audit of the financial statements**

A description of the scope of an audit of financial statements is provided on the FRC's website at [www.frc.org.uk/auditscopeukprivate](http://www.frc.org.uk/auditscopeukprivate).

#### **Opinion on financial statements**

In our opinion the financial statements:

- give a true and fair view of the state of the company's affairs as at 28 February 2014 and of its loss for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

#### **Opinion on other matters prescribed by the Companies Act 2006**

In our opinion the information given in the directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements.

#### **Emphasis of matter**

In forming our opinion on the financial statements, which is not modified, we have considered the adequacy of the disclosure made in note 1.1 to the financial statements concerning the company's ability to continue as a going concern. During the year, the company made a loss of £134,644 and has net current liabilities of £85,699 and net liabilities of £112,254. The company currently funds its operations through cash injections from its investors, a loan from Scottish Enterprise and licence fee income. The ability of the company to continue as a going concern is dependent on the ability of the company to secure new customers for its products or obtaining additional funding from its existing shareholders as it becomes required. These conditions, along with the other matters explained in note 1.1 to the financial statements, indicate the existence of a material uncertainty which may cast significant doubt about the company's ability to continue as a going concern. The financial statements do not include the adjustments that would result if the company was unable to continue as a going concern.

## SYNTROPHARMA LIMITED

### INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF SYNTROPHARMA LIMITED

#### Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the directors were not entitled to prepare the financial statements and the directors' report in accordance with the small companies regime and to the exemption from the requirement to prepare a strategic report.

*BDO LLP*

*22 SEPTEMBER 2014*

**Martin J Gill** (senior statutory auditor)  
For and on behalf of **BDO LLP**, statutory auditor  
Citypoint  
United Kingdom

BDO LLP is a limited liability partnership registered in England and Wales (with registered number OC305127).

**SYNTROPHARMA LIMITED**

**PROFIT AND LOSS ACCOUNT  
FOR THE YEAR ENDED 28 FEBRUARY 2014**

	Note	2014 £	2013 £
<b>TURNOVER</b>	1	<b>61,494</b>	-
Cost of sales		<b>(2,399)</b>	-
		<hr/>	<hr/>
<b>GROSS PROFIT</b>		<b>59,095</b>	-
Administrative expenses		<b>(229,648)</b>	(308,321)
Other operating income	2	-	19,782
		<hr/>	<hr/>
<b>OPERATING LOSS</b>	3	<b>(170,553)</b>	(288,539)
Interest payable and similar charges		<b>(628)</b>	(3,505)
		<hr/>	<hr/>
<b>LOSS ON ORDINARY ACTIVITIES BEFORE TAXATION</b>		<b>(171,181)</b>	(292,044)
Tax credit on loss on ordinary activities	5	<b>36,537</b>	241
		<hr/>	<hr/>
<b>LOSS FOR THE FINANCIAL YEAR</b>	11	<b>(134,644)</b>	(291,803)
		<hr/> <hr/>	<hr/> <hr/>

The notes on pages 7 to 12 form part of these financial statements.




**SYNTROPHARMA LIMITED**  
**REGISTERED NUMBER: SC279236**

**BALANCE SHEET**  
**AS AT 28 FEBRUARY 2014**

	Note	£	2014 £	£	2013 £
<b>FIXED ASSETS</b>					
Tangible assets	6		548		548
<b>CURRENT ASSETS</b>					
Debtors	7	88,485		6,988	
Cash at bank		60,732		184,009	
		<u>149,217</u>		<u>190,997</u>	
<b>CREDITORS:</b> amounts falling due within one year	8	<u>(234,916)</u>		<u>(129,341)</u>	
<b>NET CURRENT (LIABILITIES)/ASSETS</b>			<u>(85,699)</u>		61,656
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>			<u>(85,151)</u>		62,204
<b>CREDITORS:</b> amounts falling due after more than one year	9		<u>(27,103)</u>		<u>(39,814)</u>
<b>NET (LIABILITIES)/ASSETS</b>			<u><u>(112,254)</u></u>		<u><u>22,390</u></u>
<b>CAPITAL AND RESERVES</b>					
Called up share capital	10		6		6
Share premium account	11	2,834,736		2,834,736	
Profit and loss account	11	<u>(2,946,996)</u>		<u>(2,812,352)</u>	
<b>SHAREHOLDERS' (DEFICIT)/FUNDS</b>			<u><u>(112,254)</u></u>		<u><u>22,390</u></u>

The financial statements have been prepared in accordance with the provisions applicable to small companies within Part 15 of the Companies Act 2006 and in accordance with the Financial Reporting Standard for Smaller Entities (effective April 2008).

The financial statements were approved and authorised for issue by the board and were signed on its behalf on

  
 .....  
 Director **P K MOORE.**

The notes on pages 7 to 12 form part of these financial statements.

## **SYNTROPHARMA LIMITED**

### **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 28 FEBRUARY 2014**

#### **1. ACCOUNTING POLICIES**

##### **1.1 Basis of preparation of financial statements**

The financial statements have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard for Smaller Entities (effective April 2008).

The company made a loss of £134,644 (2013 - £291,803) in the current financial year and has net current liabilities of £85,699 and net liabilities of £112,254. The ability of the company to continue as a going concern will ultimately be dependent on the ability of the company to secure new customers for its various products or on obtaining additional funding from shareholders as it becomes required. To date, the company has been funded through capital injected by its shareholders and a loan provided by Scottish Enterprise.

Although, the company received no additional funding from its existing shareholders during the year (2013 - £218,602), further financial support may become needed in the foreseeable future to enable the company to meet its liabilities as they fall due. These conditions existing at the year-end indicate a material uncertainty that may cast significant doubt on the company's ability to continue as a going concern.

Since the year end the company has developed sales in three countries and the directors remain confident regarding the company's prospects in these countries and are in discussions with a number of parties regarding licencing of their various products in a number of international markets. The directors therefore consider it appropriate to prepare the financial statements on going concern basis.

The financial statements do not include the adjustments that would result if the company was unable to continue as a going concern.

##### **1.2 Turnover**

Turnover is measured at the fair value of the consideration received or receivable and represents amounts from the sales of goods and services (including payments received for out-licencing) provided in the normal course of business in the year, net of value added tax and discounts.

##### **1.3 Tangible fixed assets and depreciation**

Tangible fixed assets are stated at cost less depreciation. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Office equipment	-	25% straight line
------------------	---	-------------------

##### **1.4 Operating leases**

Rentals under operating leases are charged to the profit and loss account on a straight line basis over the lease term.

Benefits received and receivable as an incentive to sign an operating lease are recognised on a straight line basis over the period until the date the rent is expected to be adjusted to the prevailing market rate.

## **SYNTROPHARMA LIMITED**

### **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 28 FEBRUARY 2014**

#### **1. ACCOUNTING POLICIES (continued)**

##### **1.5 Deferred taxation**

Full provision is made for deferred tax assets and liabilities arising from all timing differences between the recognition of gains and losses in the financial statements and recognition in the tax computation.

A net deferred tax asset is recognised only if it can be regarded as more likely than not that there will be suitable taxable profits from which the future reversal of the underlying timing differences can be deducted.

Deferred tax assets and liabilities are calculated at the tax rates expected to be effective at the time the timing differences are expected to reverse.

Deferred tax assets and liabilities are not discounted.

##### **1.6 Foreign currencies**

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at rates of exchange ruling at the balance sheet date.

Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction.

Exchange gains and losses are recognised in the profit and loss account.

##### **1.7 Research and development**

Research and development expenditure includes amounts paid to third parties in relation to relevant activities and services as well as milestone and other payments for the acquisition of patents, technologies and other intellectual property. Relevant staff costs and direct and indirect overheads incurred in relation to research and development activities are also included.

Expenditure on in-house research and patents is written off as incurred. Development expenditure, including acquired product rights, is also written off, except where the directors are satisfied as to the technical, commercial and financial viability of individual projects including receipt of relevant regulatory approvals.

Expenditure on in-licensed technologies is reviewed on a consistent basis with other research and development expenditure and in-licensed costs which have uncertain future revenue are expensed as incurred.

All development expenditure to date has been written off. Where future development expenditure is considered suitable for capitalisation, the identifiable costs will be deferred and amortised over the period during which the company is expected to benefit and provision will be made for any impairment.

The costs of funding research are accounted for as incurred.

##### **1.8 Government grants**

Government grants relating to tangible fixed assets are treated as deferred income and released to the profit and loss account over the expected useful lives of the assets concerned. Other grants are credited to the profit and loss account when received.

**SYNTROPHARMA LIMITED**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 28 FEBRUARY 2014**

**1. ACCOUNTING POLICIES (continued)**

**1.9 Financial liabilities and equity**

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

**SYNTROPHARMA LIMITED**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 28 FEBRUARY 2014**

**2. OTHER OPERATING INCOME**

	<b>2014</b>	<b>2013</b>
	<b>£</b>	<b>£</b>
Grants receivable	<u>-</u>	<u>19,782</u>

**3. OPERATING LOSS**

The operating loss is stated after charging:

	<b>2014</b>	<b>2013</b>
	<b>£</b>	<b>£</b>
Auditor's remuneration	<b>4,350</b>	4,350
Research and development expenditure written off	<b>3,832</b>	86,409
Gain/(Loss) on foreign exchange	<b>186</b>	1,366

**4. DIRECTORS' REMUNERATION**

	<b>2014</b>	<b>2013</b>
	<b>£</b>	<b>£</b>
Aggregate remuneration	<u><b>153,800</b></u>	<u>144,382</u>

**5. TAXATION**

	<b>2014</b>	<b>2013</b>
	<b>£</b>	<b>£</b>
Tax credit on loss on ordinary activities	<u>(36,537)</u>	<u>(241)</u>
<b>Tax credit on loss on ordinary activities</b>	<u><b>(36,537)</b></u>	<u><b>(241)</b></u>

**6. TANGIBLE FIXED ASSETS**

	<b>Office equipment £</b>
<b>Cost</b>	
At 1 March 2013 and 28 February 2014	<u>10,859</u>
<b>Depreciation</b>	
At 1 March 2013 and 28 February 2014	<u>10,311</u>
<b>Net book value</b>	
At 28 February 2014	<u><b>548</b></u>
At 28 February 2013	<u>548</u>

**SYNTROPHARMA LIMITED**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 28 FEBRUARY 2014**

**7. DEBTORS**

	2014 £	2013 £
Trade debtors	61,686	-
Other debtors	9,038	6,988
Research and development tax credit	17,761	-
	<u>88,485</u>	<u>6,988</u>

**8. CREDITORS:  
Amounts falling due within one year**

	2014 £	2013 £
Other loans	12,028	10,186
Trade creditors	174,943	87,150
Other taxation and social security	1,344	1,344
Other creditors	46,601	30,661
	<u>234,916</u>	<u>129,341</u>

**9. CREDITORS:  
Amounts falling due after more than one year**

	2014 £	2013 £
Other loans	27,103	39,814
	<u>27,103</u>	<u>39,814</u>

**10. SHARE CAPITAL**

	2014 £	2013 £
<b>Allotted, called up and fully paid</b>		
55,115 (2013 - 53,836) Ordinary shares shares of £0.0001 each	<u>6</u>	<u>6</u>

During the year the company allotted nil (2013 - 8,408) ordinary shares with a nominal value of £0.0001 for a total consideration of £nil (2013 - £218,603) as part of fund-raising to provide financing for the company's ongoing development.

**Executive Option Scheme**

The executive option scheme was applicable to 3 directors. On 1 August 2008, 24,104 options were granted at an exercise price of £0.0001 per share. These options have not been exercised and expired on 1 August 2011. On 19 July 2012, 4,600 options were granted at an exercise price of £0.0001 per share. These options will expire on 19 July 2017.

One employee has the right to purchase 698 ordinary shares at a price of £62.40 per share. The option was granted on 1 August 2008 and will expire on 1 August 2018. No performance conditions are attached to this scheme. No charge has been recorded for Executive Option Scheme share options granted in accordance with the FRSSE.

# SYNTROPHARMA LIMITED

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 28 FEBRUARY 2014

### 10. SHARE CAPITAL (continued)

#### EMI share options

These options apply to two individuals. 2,558 options with an exercise price of £0.0001 per share were granted on 1 August 2008. During the year one employee exercised their 1,279 options. The remaining options will expire on 1 August 2018 and can be exercised at any point. There are no performance conditions attached to these options. No charge has been recorded for EMI share options granted in accordance with the FRSSE.

### 11. RESERVES

	Share premium account £	Profit and loss account £
At 1 March 2013	2,834,736	(2,812,352)
Loss for the financial year		(134,644)
	<hr/>	<hr/>
At 28 February 2014	<u>2,834,736</u>	<u>(2,946,996)</u>

### 12. RELATED PARTY TRANSACTIONS

During the year, fees totalling £24,500 (2013 - £15,200), £16,800 (2013 - £14,800) and £24,000 (2013 - £22,000) were invoiced by I J G Scott, G McGettigan and P K Moore respectively, for services provided as non executive directors. These fees were invoiced by their respective companies.

Included within trade creditors are amounts of £58,828 (2013 - £23,951), £36,989 (2013 - £12,880) and £53,593 (2013 - £20,556) due to JGS Associates (Scotland) Limited, Celtic Bio-Pharma Limited and Business Therapies Limited, companies controlled by I J G Scott, G McGettigan and P K Moore respectively. The maximum outstanding during the year was £58,828 (2013 - £23,951), £36,989 (2013 - £12,880) and £53,593 (2013 - £20,556) respectively.

Included within other creditors are amounts of £5,832 (2013 - £5,832) and £992 (2013 - £992) payable to A Gardiner and D McHoul, both directors.

During the year nil (2013 - 296) ordinary shares were issued to Celtic Bio Services Limited, a company controlled by G McGettigan, a director.

During the year nil (2013 - 443) ordinary shares were issued to Business Therapies Limited, a company controlled by P K Moore, a director.

During the year nil (2013 - 296) ordinary shares were issued to JGS Associates (Scotland) Limited, a company controlled by I J G Scott, a director.

### 13. CONTROLLING PARTY

In the opinion of the board of directors and by virtue of their respective shareholdings, there is no one individual party that exercises control of the company.